- Home
- PRTA
as 04-25-2025 4:00pm EST
Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).
| Founded: | 2012 | Country: | Ireland |
| Employees: | N/A | City: | DUBLIN 2 |
| Market Cap: | 809.8M | IPO Year: | N/A |
| Target Price: | $54.57 | AVG Volume (30 days): | 605.6K |
| Analyst Decision: | Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.27 | EPS Growth: | N/A |
| 52 Week Low/High: | $9.00 - $25.42 | Next Earning Date: | 05-07-2025 |
| Revenue: | $135,157,000 | Revenue Growth: | 47.92% |
| Revenue Growth (this year): | -62.18% | Revenue Growth (next year): | 131.71% |
Latest Prothena Corporation plc News
PRTA Breaking Stock News: Dive into PRTA Ticker-Specific Updates for Smart Investing
Simply Wall St.
2 months ago
Prothena Full Year 2024 Earnings: Misses Expectations
Zacks
2 months ago
Prothena Q4 Earnings Miss Estimates, Pipeline Progress in Focus
MT Newswires
2 months ago
RBC Cuts Price Target on Prothena to $20 From $24, Keeps Sector Perform, Speculative Risk
GuruFocus.com
2 months ago
Prothena Corp PLC (PRTA) Q4 2024 Earnings Call Highlights: Strong Financial Position Amidst ...
Zacks
2 months ago
Prothena (PRTA) Reports Q4 Loss, Misses Revenue Estimates
Associated Press Finance
2 months ago
Prothena: Q4 Earnings Snapshot
Business Wire
2 months ago
Prothena Reports Fourth Quarter and Full Year 2024 Financial Results, and Provides Financial Guidance and Business Highlights
Business Wire
2 months ago
Prothena to Report Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025
Compare PRTA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PRTA Prothena Corporation plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.